Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Aerts

Showing results (61-70 of 360) with videos related to

Pageof 36
Sort By:
Expert Opinion on Therapeutic Targets|May 17, 2007
Novel therapeutic targets for the treatment of Fabry diseaseCarla E M Hollak, Anouk C Vedder, Gabor E Linthorst, et al.
Organic & Biomolecular Chemistry|July 20, 2011
Irreversible inhibitors and activity-based probes as research tools in chemical glycobiologyMartin D Witte, Gijsbert A van der Marel, Johannes M F G Aerts, et al.
American Journal of Respiratory and Critical Care Medicine|March 15, 2005
Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cellsJoost P J J Hegmans, Annabrita Hemmes, Joachim G Aerts, et al.
BMC Cancer|December 11, 2012
Patient-tailored modulation of the immune system may revolutionize future lung cancer treatmentMarlies E Heuvers, Joachim G Aerts, Robin Cornelissen, et al.
FEBS Letters|July 7, 2022
In situ glucosylceramide synthesis and its pharmacological inhibition analysed in cells by <sup>13</sup> C<sub>5</sub> -sphingosine precursor feeding and mass spectrometryRebecca E Katzy, Maria J Ferraz, Marc Hazeu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 10, 2019
Early-Stage NSCLC: Advances in Thoracic Oncology 2018Raymond U Osarogiagbon, Giulia Veronesi, Wentao Fang, et al.
Frontiers in Cell and Developmental Biology|December 24, 2019
Glycosphingolipids and Infection. Potential New Therapeutic AvenuesJohannes M F G Aerts, M Artola, M van Eijk, et al.
Journal of Inherited Metabolic Disease|October 4, 2007
Hypermetabolism in Gaucher disease type I is not associated with altered thyroid hormone levelsM Langeveld, E Endert, W M Wiersinga, et al.
Molecular Genetics and Metabolism|October 10, 2008
Enzyme replacement therapy in Fabry disease: towards a better understanding of the implications of antibody formation and doseC E M Hollak, A C Vedder, B Winchester, et al.
FEBS Letters|February 1, 2024
Mitochondrial dysfunction in NPC1-deficiency is not rescued by drugs targeting the glucosylceramidase GBA2 and the cholesterol-binding proteins TSPO and StARD1Simon Wheeler, Meenakshi Bhardwaj, Victor Kenyon, et al.
Pageof 36

Showing results (61-70 of 360) with videos related to

Sort By:
Pageof 36
Expert Opinion on Therapeutic Targets|May 17, 2007
Novel therapeutic targets for the treatment of Fabry diseaseCarla E M Hollak, Anouk C Vedder, Gabor E Linthorst, et al.
Organic & Biomolecular Chemistry|July 20, 2011
Irreversible inhibitors and activity-based probes as research tools in chemical glycobiologyMartin D Witte, Gijsbert A van der Marel, Johannes M F G Aerts, et al.
American Journal of Respiratory and Critical Care Medicine|March 15, 2005
Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cellsJoost P J J Hegmans, Annabrita Hemmes, Joachim G Aerts, et al.
BMC Cancer|December 11, 2012
Patient-tailored modulation of the immune system may revolutionize future lung cancer treatmentMarlies E Heuvers, Joachim G Aerts, Robin Cornelissen, et al.
FEBS Letters|July 7, 2022
In situ glucosylceramide synthesis and its pharmacological inhibition analysed in cells by <sup>13</sup> C<sub>5</sub> -sphingosine precursor feeding and mass spectrometryRebecca E Katzy, Maria J Ferraz, Marc Hazeu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 10, 2019
Early-Stage NSCLC: Advances in Thoracic Oncology 2018Raymond U Osarogiagbon, Giulia Veronesi, Wentao Fang, et al.
Frontiers in Cell and Developmental Biology|December 24, 2019
Glycosphingolipids and Infection. Potential New Therapeutic AvenuesJohannes M F G Aerts, M Artola, M van Eijk, et al.
Journal of Inherited Metabolic Disease|October 4, 2007
Hypermetabolism in Gaucher disease type I is not associated with altered thyroid hormone levelsM Langeveld, E Endert, W M Wiersinga, et al.
Molecular Genetics and Metabolism|October 10, 2008
Enzyme replacement therapy in Fabry disease: towards a better understanding of the implications of antibody formation and doseC E M Hollak, A C Vedder, B Winchester, et al.
FEBS Letters|February 1, 2024
Mitochondrial dysfunction in NPC1-deficiency is not rescued by drugs targeting the glucosylceramidase GBA2 and the cholesterol-binding proteins TSPO and StARD1Simon Wheeler, Meenakshi Bhardwaj, Victor Kenyon, et al.
Pageof 36